Gilead Sciences, Inc.
General ticker "GILD" information:
- Sector: Health Care
- Industry: Drug Manufacturers - General
- Capitalization: $161.8B (TTM average)
Gilead Sciences, Inc. follows the US Stock Market performance with the rate: 24.2%.
Estimated limits based on current volatility of 1.7%: low 153.38$, high 158.70$
Factors to consider:
- Earnings expected soon, date: 2026-10-29 amc
- Company included in S&P500 list
- Company included in NASDAQ-100 index
- Company pays dividends (quarterly): last record date 2026-09-15, amount 0.82$ (Y2.10%)
- Total employees count: 17000 (-3.4%) as of 2025
- US accounted for 37.8% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Manufacturing failures, Product development failure, Regulatory and compliance, Safety incidents, Supply chain disruptions
- Current price 25.3% above estimated high
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [84.91$, 124.68$]
- 2026-12-31 to 2027-12-31 estimated range: [87.42$, 127.86$]
Financial Metrics affecting the GILD estimates:
- Negative: with PPE of 15.3 at the end of fiscal year the price was high
- Positive: Operating profit margin, % of 34.04 > 33.79
- Positive: 4.90 < Operating cash flow per share per price, % of 6.48
- Positive: 5.56 < Industry operating cash flow per share per price (median), % of 5.61
- Positive: Industry inventory ratio change (median), % of 0.50 <= 1.15
- Positive: -4.49 < Investing cash flow per share per price, % of -3.10
- Positive: Return on assets ratio (scaled to [-100,100]) of 12.60 > 10.70
- Positive: 14.78 < Industry operating profit margin (median), % of 24.67
- Positive: 34.41 < Shareholder equity ratio, % of 38.46 <= 42.26
Short-term GILD quotes
Relationship graph
Long-term GILD plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $27,116.00MM | $28,754.00MM | $29,443.00MM |
| Operating Expenses | $19,511.00MM | $27,092.00MM | $19,421.00MM |
| Operating Income | $7,605.00MM | $1,662.00MM | $10,022.00MM |
| Non-Operating Income | $-746.00MM | $-972.00MM | $-226.00MM |
| Interest Expense | $944.00MM | $977.00MM | $1,024.00MM |
| R&D Expense | $5,718.00MM | $5,907.00MM | $5,799.00MM |
| Income(Loss) | $6,859.00MM | $690.00MM | $9,796.00MM |
| Taxes | $1,247.00MM | $211.00MM | $1,286.00MM |
| Net Income(Loss)* | $5,665.00MM | $480.00MM | $8,510.00MM |
| Stockholders Equity | $22,833.00MM | $19,330.00MM | $22,702.00MM |
| Inventory | $1,787.00MM | $1,710.00MM | $1,774.00MM |
| Assets | $62,125.00MM | $58,995.00MM | $59,023.00MM |
| Operating Cash Flow | $8,006.00MM | $10,828.00MM | $10,019.00MM |
| Capital expenditure | $585.00MM | $523.00MM | $563.00MM |
| Investing Cash Flow | $-2,265.00MM | $-3,449.00MM | $-4,793.00MM |
| Financing Cash Flow | $-5,125.00MM | $-3,433.00MM | $-7,745.00MM |
| Earnings Per Share** | $4.54 | $0.38 | $6.84 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.